P. Martin

Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

D. Baker, P. Hochman, R. Pepinsky, 2001, The Journal of pharmacology and experimental therapeutics.

Hepatotoxicity of anesthetics and other central nervous system drugs.

C. Holt, P. Martin, M. Csete, 1995, Gastroenterology clinics of North America.

Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment

J. Grippo, K. Nieforth, P. Martin, 2013, Antimicrobial Agents and Chemotherapy.

Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study

A. Zaman, S. Troy, Patrick Martin, 2014, Thrombosis and Haemostasis.

PHARMACOKINETICS AND DISPOSITION Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment

S. G. Simonson, K. Lasseter, P. Martin, 2003 .

Digoxin pharmacokinetics in patients with high serum digoxin concentrations

P. Martin, A. Domínguez-Gil, M. V. Calvo, 1993, Journal of clinical pharmacy and therapeutics.

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

P. Beale, T. Hickish, I. Judson, 1998, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas

L. Aarons, J. Fangusaro, P. Martin, 2017, CPT: pharmacometrics & systems pharmacology.